Kezar Life Sciences Receives FDA Clearance of IND for Zetomipzomib for the Treatment of Autoimmune Hepatitis

Kezar Life Sciences, Inc. announced that it received clearance of its Investigational New Drug (IND) application from the U.S. FDA for zetomipzomib, its first-in-class, selective immunoproteasome inhibitor, for the treatment of autoimmune hepatitis.